Amgen dropped on read-through from a rival Phase 3 failure, but its drug uses a different siRNA method and analyst views remained mixed, so the report does not change Amgen's outlook.
Amgen shares fell after a competing Lp(a) drug failed a Phase 3 outcomes trial. The rival result raises questions, but Amgen's drug uses a different siRNA approach and analyst views stayed mixed, so the report does not change Amgen's outlook.
Novartis reported that its Phase 3 Lp(a) drug failed to meet the trial's primary endpoint, which weakens prospects for that program.
Follow Amgen Inc. (AMGN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AMGN